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Background. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-
monocyte ratio (LMR) were analyzed in various carcinomas and their potential prognostic significance was deter-
mined. The objective of present study was to determine the correlation between these parameters and the survival 
of patients with small cell lung cancer (SCLC), since very few studies have been published on this type of carcinoma.
Patients and methods. One hundred and forty patients diagnosed with SCLC at University Hospital Center Zagreb, 
between 2012 and 2016 were retrospectively analyzed. Extensive-stage disease (ED) was verified in 80 patients and 
limited-stage disease (LD) in 60 patients. We analyzed the potential prognostic significance of various laboratory pa-
rameters, including NLR, PLR, and LMR, measured before the start of treatment.
Results. Disease extension, response to therapy, chest irradiation and prophylactic cranial irradiation (PCI), as well 
as hemoglobin, monocyte count, C-reactive protein (CRP), and lactate dehydrogenase (LDH) showed a prognostic 
significance in all patients. When we analyzed the patients separately, depending on the disease extension, we found 
that only skin metastases as well as LDH and NLR values, regardless of the cut-off value, had a prognostic significance 
in ED. Meanwhile, the ECOG performance status, chest irradiation, PCI, and hemoglobin and creatinine values had 
a prognostic significance in LD.
Conclusions. NLR calculated before the start of the treatment had a prognostic significance for ED, while PLR and 
LMR had no prognostic significance in any of the analyzed groups of patients. 
Key words: small cell lung cancer; hematological markers; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte 
ratio; lymphocyte-to-monocyte ratio
Introduction
Lung cancer is still one of the most malignant dis-
eases nowadays. It is the most commonly occur-
ring cancer in men and the second most commonly 
occurring cancer in women according to the lat-
est data by the International Agency for Research 
on Cancer (IACR).1 At the same time, lung cancer 
is the leading cause of cancer death among both 
men and women. For the purposes of comparison, 
breast cancer in women occurs three times more of-
ten than lung cancer, while the mortality is almost 
equal. Moreover, prostate cancer and lung cancer 
have almost the same incidence in men, but the 
lung cancer mortality rate is four times higher than 
the prostate cancer mortality rate.1,2 
Small cell lung cancer (SCLC) is the most aggres-
sive subtype of lung cancer. Nowadays, small cell 
lung cancer makes up about 15% of all lung can-
cers and occurs almost only in smokers. The inci-
dence of this lung cancer subtype has decreased in 
the last few decades, but primarily in developed 
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countries.3,4 There are no global data on SCLC prev-
alence. In Croatia, there are no separate data on 
SCLC either, and the available epidemiological data 
relate to lung cancer as an entity. In the last twenty 
years, a slight reduction in the share of SCLC in re-
lation to the total number of lung cancer patients 
has been observed at our institution, which is the 
largest thoracic oncology center in the country.
According to literature there are differences in 
survival rates for various tumors, including small 
cell lung cancer, depending on ethnic origin.5 
Therefore, the results of epidemiological and clini-
cal studies in one geographic area are not applica-
ble to some other geographic areas. 
The main characteristics of small cell lung can-
cer are its rapid growth and early spread to distal 
body parts. This is the reason why in most cases 
this carcinoma is diagnosed late, when metastatic 
disease has already developed.6 Surgical treat-
ment is therefore rarely possible, but in the last 
few years it has been recommended for certain pa-
tients with early-stage disease.7 Before the intro-
duction of platinum-based antineoplastic drugs 
for the treatment of malignant disease, the median 
survival of patients diagnosed with small cell lung 
cancer was two to three months.8,9 The survival 
rate has increased four to five times with chemo-
therapy, but for most patients with extensive-stage 
disease it does not exceed ten months. In fact, this 
tumor is extremely chemosensitive and usually 
responds to chemotherapy very well. However, it 
recurs very rapidly and most patients die after a 
relapse. Despite numerous clinical trials, progress 
in the treatment of small cell lung cancer has been 
modest. However, as treatment of limited disease 
(LD) became more successful with the introduc-
tion of thoracic radiotherapy and prophylactic 
cranial irradiation (PCI), concurrent chemoradio-
therapy has been a standard in the treatment of 
LD for a long time now.6 The optimal radiation 
therapy protocol has remained controversial un-
til this day, although it has been established that 
there are no differences in either survival or tox-
icity between hyperfractionated and normofrac-
tionated radiotherapy.10,11 The application of con-
solidation radiotherapy in selected patients with 
extensive-stage disease (ED) and a good initial re-
sponse to chemotherapy have partly contributed 
to the improved survival rate, but application has 
been very inconsistent.12,13 Immunotherapy has 
resulted in significant progress in the treatment 
of numerous malignant diseases, including non-
small cell lung cancer (NSCLC). Expectations for 
the treatment of small cell lung cancer were high 
as well. For the time being, adding checkpoint in-
hibitors to first-line chemotherapy in ED has re-
sulted in a slight increase of overall survival and 
progression-free survival, but the results are far 
from expected.14-16
It is well known that infection and deregulated 
inflammatory response are associated with the oc-
currence and progression of almost all chronic dis-
eases, including cancers.17 In the last few decades, 
a great number of researches investigating the role 
of different inflammatory markers in cancer de-
velopment and outcome have been published.18-20 
Usually the investigated inflammatory markers in-
clude C-reactive protein (CRP), lactate dehydroge-
nase (LDH), erythrocyte sedimentation rate, plate-
let (Pc) and neutrophil counts.21-23 In most cases, it 
has been found that elevated levels of these param-
eters are associated with poorer outcome of vari-
ous cancers, including small cell lung cancer.24,25 
On the other hand, the lymphocyte count reflects 
the immunological status of a host, thus a low lym-
phocyte count is a predictor of poorer outcome.26 
The prognostic value of combinations of these and 
other parameters has also been extensively investi-
gated. Among them, the neutrophil-to-lymphocyte 
ratio in various chronic diseases, including numer-
ous malignant diseases, has been investigated the 
most.27-29
In this study, we have investigated CRP, LDH, 
Pc, hemoglobin (Hb), creatinine, neutrophil-to-
lymphocyte ratio (NLR), platelet-to-lymphocyte 
ratio (PLR), and lymphocyte-to-monocyte ratio 
(LMR) and their impact on the outcome of patients 
with SCLC. To the best of our knowledge, this is the 
first study carried out exclusively on a European 
population which investigated the prognostic sig-
nificance of all three mentioned ratios in patients 
with limited-stage and extensive-stage small cell 
lung cancer.29-31
Patients and methods
Patients
For research purposes, we analyzed the medical 
records of 438 patients diagnosed with small cell 
lung cancer admitted to the University Hospital 
Center, Department for Lung Diseases Jordanovac 
between 2012 and 2016. We included only patients 
whose disease was verified by histopathological 
analysis and who had undergone first-line chemo-
therapy or chemoradiotherapy. Some additional 
criteria needed to be met in order to be included 
in the research: documented laboratory test results 
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with the investigated parameters measured up to 
three weeks before the first chemotherapy, as well 
as data on performance status, follow up, and out-
come. The following patient categories were ex-
cluded from further research: surgically treated 
patients, patients with combined small cell lung 
carcinoma, patients with one or more synchronous 
tumors, patients who received no therapy, patients 
without the required medical records, and patients 
lost to follow-up. After exclusion of the mentioned 
groups, 140 patients remained who met all the re-
quired inclusion and exclusion criteria for further 
investigation. Out of the total number of patients, 
80 were diagnosed with extensive-stage disease 
and 60 with limited-stage disease. The patients’ 
performance status was measured before the start 
of the treatment and defined according to the 
Eastern Cooperative Oncology Group Performance 
Status (ECOG) scale.32 Regarding the ECOG status, 
the patients were divided into two groups: good 
ECOG status (0–1) and poor ECOG status (2–3).
All patients underwent a thoracic and abdominal 
computed tomography (CT) scan before the start of 
the treatment. Skeletal scintigraphy was done only 
in cases with a clinical indication, because it was 
not routinely performed at our Department. The 
same applied to brain CT scanning. Disease exten-
sion was defined according to the staging system 
established by the International Association for 
the Study of Lung Cancer (IASLC) in 1989, which 
divides SCLC into two stages, “limited-stage dis-
ease” and “extensive-stage disease”.33 The patients 
underwent follow-up chest X-ray scans after every 
two chemotherapy cycles. A follow-up CT scan 
was performed after the treatment was completed, 
especially in cases of initial limited-stage disease. 
Regression of a primary tumor and metastasis or 
stable disease was marked as response to therapy 
what was in fact disease control after initial thera-
py, whereas progression of the disease was marked 
as no-response. Response to therapy was assessed 
radiologically and clinically (e.g., if a patient had 
subcutaneous metastases or palpable lymph nodes 
in a region which had not been examined by CT).  
In our institution, patients usually receive 4–6 
cycles of the first-line platinum-doublet chemo-
therapy. Patients who received a minimum of two 
and a maximum of six cycles of the mentioned 
chemotherapy, with or without radiotherapy, were 
included in the study. A concomitant or sequential 
radiotherapy protocol was carried out, primarily 
in patients with limited-stage disease or as pal-
liative treatment in patients with extensive-stage 
disease and a good response to chemotherapy. 
Prophylactic cranial irradiation was mainly per-
formed in patients with limited-stage disease.
Data collection and ethical consideration
Data were collected by using the electronic infor-
mation database, based on good clinical practice 
and complying with international standards in-
cluding the Helsinki Declaration on Patient Safety. 
We obtained approval for data collection and anal-
ysis by the Ethics Committee of our institution. 
Since this was a retrospective study, informed con-
sent was not required. 
Demographic, laboratory, cytological, histo-
pathological, clinical, and treatment data were 
collected on the patients included in the study. 
Laboratory test results obtained shortly before 
the start of treatment, that is, a maximum of three 
weeks before the first chemotherapy, were included 
in the study. Among all the hematological results, 
the following parameters were analyzed: leukocyte 
count, lymphocyte count, neutrophil count, mono-
cyte count, platelets, hemoglobin, CRP, creatinine, 
and LDH. The neutrophil-to-lymphocyte ratio was 
calculated by dividing the total neutrophil count 
by the total lymphocyte count. The platelet-to-lym-
phocyte and lymphocyte-to-monocyte ratios were 
calculated in the same way. 
Overall survival (OS) was defined as the length 
of time from the date of diagnosis to death from 
any cause, or the last follow-up for patients who 
were still alive. Progression-free survival (PFS) was 
defined as the length of time from diagnosis to pro-
gression or death, depending on what happened 
first.
Statistical analysis
For the analysis of demographic and clinical da-
ta, we used descriptive and inferential statistical 
methods. Parameters are indicated as sum and per-
centage, arithmetic mean +/- standard deviation, or 
as interquartile range limits with the median as a 
measure of the central tendency. Differences among 
the ranked parameters, i.e., the investigated values, 
were calculated by using the Mann–Whitney U 
test. Differences among categorical data were test-
ed by using the Chi-square test with Fisher’s exact 
test for smaller samples. Intercorrelation among 
the variables was tested by using Spearman’s rank 
correlation coefficient varying within the closed in-
terval –1 ≤ r ≤ +1. For survival analysis, the Kaplan–
Meier estimator was used, and the Log-rank test 
(Mantel-Cox) was used as a test of significance. The 
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or for clinically relevant parameters. All P values 
were two-tailed. The level of significance was set 
at Alpha = 0.05. Statistical analysis was performed 
by using IBM SPSS Statistics for Windows, Version 
21.0 (IBM SPSS Inc, Chicago, IL, USA). 
Cut-off values suggested by the literature were 
used for testing the potential prognostic value of 
the investigated ratios, since the ROC curves of the 
investigated ratios did not have a statistical signifi-
cance. All ratios were tested regarding two cut-off 
values. The cut-off values for NLR were 4 and 5, 
those for PLR were 150 and 250, and those for LMR 
were 2.64 and 4.19.34-39
Results
Patient characteristics
Patient characteristics regarding the disease stage 
are shown in Table 1. Out of 438 patients diag-
nosed with small cell lung cancer or mixed neu-
roendocrine carcinoma between 2012 and 2016, 
140 met the inclusion and exclusion criteria and 
were included in the study. Of those 140 patients, 
80 were diagnosed with extensive-stage disease 
and 60 with limited-stage disease. The mean pa-
tient age was 63.1 years with a mean deviation of 
9.2 years (42–87 years of age). Slightly more males 
than females were involved in the study (89 or 
63.6%). The majority of the patients were smokers 
(95.7%), of good performance status, 0–1 according 
to the ECOG scale (82.9%). Only 14 patients (10%) 
received less than 4 chemotherapy cycles. Forty-
five patients (32%) underwent radiotherapy, most 
of whom were in the limited-stage disease group. 
Only twelve patients underwent PCI (8.6%), again 
significantly more in the limited-stage disease 
group. Disease control was observed in 119 patients 
(85%). After two years, 125 patients (89.2%) died. 
Fifteen out of the total number of patients included 
in the analysis (10.7%) survived for more than 2 
years, and all of them belonged to the limited-stage 
disease group. According to the statistical analysis, 
disease control, PFS, OS, and outcome were signifi-
cantly better in the limited-stage disease group. Of 
the laboratory parameters, a significant statistical 
difference regarding the disease stage was only ob-
served for CRP and LDH. The mean NLR and PLR 
values were higher in the extensive-stage disease 
group of patients, while the mean LMR value was 
higher in the limited-stage disease group, but the 
difference was not statistically significant. In the 
extensive-stage disease group, a statistically signif-
icant difference of LMR values regarding patient 
TABLE 1. Patient characteristics regarding the disease stage
Variable ED-SCLC (n = 80) LD-SCLC (n = 60) p-values 
Age (years)
  x (SD) 63.2 (9.1) 63.0 (9.4) 0.930
Gender 
  Male
  Female
55 (68.8%)
25 (31.2%)
34 (56.7%)
26 (43.4%)
0.159
Smoking
  Yes
  No
77 (96.2%)
3 (3.8%)
57 (95.0%)
3 (5.0%)
1.000
PS (ECOG)
  0–1
  2–3
64 (80.0%)
16 (20.0%)
52 (86.7%)
8 (13.3%)
0.368
Chest irradiation
  Yes
  No
9 (11.2%)
71 (88.8%)
36 (60.0%)
24 (40.0%)
< 0.0001
PCI
  Yes
  No
2 (2.5%)
78 (97.5%)
10 (16.7%)
50 (83.3%)
0.004
Disease control
  Yes
  No
63 (78.8%)
17 (21.2%)
56 (93.3%)
4 (6.7%)
0.018
PFS (weeks)
  x (SD) 30.1 (14.5) 60.3 (57.9) < 0.0001
OS (weeks)
  x (SD) 48.3 (23.4) 83.3 (59.3) < 0.0001
Outcome
  dead
  alive
79 (98.8%)
1 (1.2%)
46 (76.7%)
14 (23.3%)
0.013
WBC count (x 109/l)
  x (SD) 9.1 (3.7) 9.2 (3.3) 0.686
Platelet count (x 
109/l)
  x (SD) 293 (119) 304 (95)
0.249
Hemoglobin (g/l)
  x (SD) 130.9 (17.8) 133.0 (16.8) 0.540
CRP (mg/l)
  x (SD) 34.2 (44.6) 21.2 (26.6) 0.048
Creatinine (umol/l)
  x (SD) 81.9 (20.0) 82.3 (29.6) 0.443
LDH (U/l)
  x (SD) 336.2 (193.5) 311.1 (607.3) 0.004
Lymphocytes (x 
109/l)
  x (SD) 1.6 (0.8) 1.7 (0.7)
0.202
Neutrophils (x 109/l)
  x (SD) 6.6 (3.4) 6.6 (3.2) 0.812
Monocytes (x109/l)
  x (SD) 0.7 (0.3) 0.7 (0.3) 0.700
NLR 
  x (SD) 5.1 (3.6) 4.6 (3.4) 0.485
PLR
  x (SD) 217.9 (119.9) 213.4 (123.3) 0.714
LMR 
  x (SD) 2.5 (1.4) 3.0 (2.4) 0.271
CRP = C-reactive protein; ECOG = Eastern Cooperative Oncology Group; ED-SCLC = extensive-
stage disease small cell lung cancer; LDH = lactate dehydrogenase; LD-SCLC = limited-stage 
disease small cell lung cancer; LMR = lymphocyte-to-monocyte ratio; NLR = neutrophil-to-
lymphocyte ratio; OS = overall survival; SD = standard deviation; PCI = prophylactic cranial 
irradiation; PFS = progression- free survival; PLR = platelet-to-lymphocyte ratio; PS = performance 
status; WBC = white blood cells; x = arithmetic mean
Cox regression was used for determining possible 
multiple interactions among the parameters. The 
Cox regression was performed in the case of p < 0.3 
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age was observed, i.e., higher LMR values were ob-
served in the younger age group.
Survival analysis
The median survival time for all patients was 52.6 
weeks (95% confidence interval [CI] 47.5–57.7). 
The median survival time for the ED group of pa-
tients was 45.7 weeks (95% confidence interval [CI] 
42.3–49.2) and for the LD patient group it was 64.1 
weeks (95% confidence interval [CI] 56.70–71.6).
According to the Kaplan-Meier estimator, sur-
vival analysis of all 140 patients showed a statisti-
cally significant difference in the overall survival 
regarding disease extension, radiotherapy to the 
primary tumor, prophylactic brain irradiation 
and disease control. Therefore, patients with lim-
ited-stage disease, patients with disease control, 
irradiated patients and patients who underwent 
PCI had a better survival. Of the laboratory pa-
rameters, a statistically significant difference in 
the overall survival was observed regarding the 
hemoglobin, CRP, LDH, and boundary monocyte 
values, whereas a statistically significant differ-
ence in the overall survival regarding the ECOG 
status, NLR, PLR, and LMR was not observed 
(Table 2). 
Separate testing showed a statistically signifi-
cant difference in overall survival in patients with 
extensive-stage disease, considering the presence 
of skin metastases and laboratory parameters in-
cluding LDH and NLR, regardless of the cut-off 
values. Therefore, a better overall survival was 
observed in the patients who did not have skin 
metastases and had lower LDH and NLR values 
(Table 3). No positive correlation between overall 
survival and ECOG status, number of metastatic 
sites, and disease control was observed in the sub-
jects with metastatic disease.
A statistically significant difference in overall 
survival, regarding the ECOG status, radiotherapy 
of the primary tumor, prophylactic cranial irra-
diation, and laboratory values such as hemoglobin 
and creatinine levels, was determined in the limit-
ed-stage disease group of patients (Table 4).
As we have already mentioned, Cox regres-
sion was used for determining possible multiple 
interactions among the variables. Thus, all statisti-
cally significant parameters from the Kaplan-Meier 
analysis were included in the multiple regression 
model. In this model LDH became the most signifi-
cant prognostic factor in extensive-stage disease, 
while the ECOG performance status became the 
TABLE 2. Prognostic parameters for survival – all patients
Variable No. of  patients
Median survival 
(weeks) - 95% CI
p-values 
(log-rank test)
Extent of 
disease
LD 
ED 
60
80
64.1 (56.7–71.6)
45.7 (42.3–49.2) < 0.0001
Chest 
irradiation
Yes
No 
45
95
69.1 (63.3–75.0)
45.3 (39.0–51.6) < 0.0001
PCI YesNo
12
128
69.0 (12.3–125.7)
49.1 (43.4–54.9) 0.003
Disease 
control
Yes
No
119
21
53.4 (49.5–57.3)
36.4 (25.3–47.5) 0.013
Hemoglobin 
(g/l)
M ≥ 138   F ≥ 119
    < 138      < 119
78
62
57.1 (50.6–63.6)
40.6 (28.9–52.3) 0.006
CRP (mg/l) < 5.0≥ 5.0
35
104
57.1 (48.9–65.4)
47.9 (41.4–54.3) 0.026
LDH (U/l) < 241≥ 241
55
56
63.0 (53.0–73.0)
37.0 (27.7–46.3) 0.002
Monocytes 
(x109/l)
≤ 0.84
> 0.84
99
41
55.0 (49.5–60.5)
44.3 (33.2–55.4) 0.048
CRP = C-reactive protein; ED = extensive-stage disease; LD = limited-stage disease; LDH - lactate 
dehydrogenase; PCI = prophylactic cranial irradiation 
TABLE 3. Prognostic parameters for survival – extensive-stage disease (ED)
Variable No. of  patients
Median survival 
(weeks) - 95% CI
p-values 
(log-rank test)
Skin metastases YesNo
4
76
15.9 (0.7–31.0)
46.9 (42.7–51.0) < 0.0001
LDH (U/l) < 241≥ 241
26
36
54.0 (45.4–62.6)
33.7 (22.8–44.6) 0.017
NLR < 4≥ 4
40
40
50.1 (43.5–56.8)
44.7 (37.4–52.0) 0.026
NLR < 5≥ 5
50
30
50.1 (44.7–55.6)
39.6 (30.7–48.5) 0.036
LDH = lactate dehydrogenase; NLR = neutrophil-to-lymphocyte ratio 
most powerful one in limited-stage disease. The 
data are presented in Table 5. 
Discussion
Numerous prognostic factors were investigated 
in various cancer types in order to find the factor 
which would most accurately define the patient 
groups that could benefit from a certain therapy 
and consequently expect a better survival.39 The 
established fact about the important role inflam-
mation plays in the process of carcinogenesis has 
led to research into the prognostic significance of 
various inflammatory markers. In the past decade 
numerous papers have been published on such 
research in relation to non-small cell lung can-
cer29,31, but, very few studies of this kind have been 
done for small cell lung cancer. The present study 
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was conducted with the intention to determine 
potential prognostic parameters of survival in a 
European population of patients diagnosed with 
SCLC. Survival parameters were identified for the 
whole population of patients, as well as separately 
for patients with extensive-stage and those with 
limited-stage disease, in order to determine differ-
ences between these two groups. 
As disease extension and performance status are 
generally among the most investigated prognostic 
parameters, they were verified as the most impor-
tant for SCLC as well.23 Our study also showed that 
disease extension was a significant prognostic fac-
tor, and certainly the most significant predictor of 
longer survival. On the other hand, performance 
status showed a prognostic value only for the 
limited-stage disease patient group, which can be 
explained by the fact that it was possibly assessed 
more accurately in this patient group. As a matter 
of fact, performance status assessment is a subjec-
tive method and in retrospective studies there is 
always a possibility that the criteria for certain pa-
tients varied. Unlike in other neoplasms, age did 
not have a prognostic significance in most of the 
studies regarding SCLC, which was confirmed in 
our study, too.23 Neither gender nor smoking sta-
tus had a prognostic significance, but, it is note-
worthy that the number of non-smokers in the 
study was negligible. Of all the variables, radio-
therapy, PCI and disease control had a survival im-
pact in the whole research patient group. When we 
separated the patients with extensive-stage from 
those with limited-stage disease, radiotherapy and 
PCI retained a survival impact in the patients with 
limited-stage disease, as we expected. However, 
disease control showed prognostic value neither in 
LD nor in ED.
In the last few decade various laboratory param-
eters regarding prognostic value have been inves-
tigated. Their ratios have also been investigated 
recently. Some studies verified a prognostic signifi-
cance of hemoglobin, leukocyte count, CRP, LDH, 
and serum sodium concentration in SCLC.23,25,40 
The prognostic significance of hemoglobin and 
LDH was confirmed in our patients, along with a 
lower significance of CRP and monocyte count as 
prognostic factors. When we excluded disease ex-
tension from the analysis, LDH retained a prognos-
tic significance in the ED group, while hemoglobin 
retained a prognostic significance in the LD group 
of patients. Besides, creatinine level occurred as 
an independent prognostic factor for survival in 
the LD group of patients, but again only in the ex-
tremely small number of patients with increased 
creatinine levels. 
Although the combinations of various labora-
tory indicators, including NLR, PLR, and LMR, 
have already been examined as prognostic factors 
in SCLC, a relatively small number of studies have 
been published regarding this type of cancer. Most 
of the published papers investigating the predic-
tive significance of these parameters in patients 
with lung cancer address non-small cell lung car-
cinoma.29-31 Consulting the literature in English 
until May, 2020, we found a total of twenty stud-
ies, seven of which had been published in 2019, 
which investigated one or more of these three 
ratios in patients with small cell lung cancer.  It is 
interesting to note that most of the studies relate 
to the Asian population. For example, the prog-
TABLE 4. Prognostic parameters for survival – limited-stage disease (LD)
Variable No. of  patients
Median survival 
(weeks) - 95% CI
p-values 
(log-rank test)
PS (ECOG) 0–12–3
52
8
66.3 (57.6–75.0)
35.9 (8.3–63.4) 0.007
Chest 
irradiation
Yes 
No
36
24
70.7 (51.8–89.6)
36.7 (16.1–57.3) 0.003
PCI Yes No
10
50
102.0 (0.0–209.6)
58.3 (46.7–69.8) 0.032
Hemoglobin 
(g/l)
M ≥ 138   F ≥ 119
    < 138      < 119
35
25
71.9 (57.0–86.8)
54.3 (17.7–90.9) 0.033
Creatinine 
(umol/l)
M < 125   F < 107
     ≥ 125      ≥ 107
57
3
66.3 (58.6–74.0)
32.9 (27.8–37.9) 0.001
ECOG = Eastern Cooperative Oncology Group; PCI = prophylactic cranial irradiation; PS = 
performance status
TABLE 5. Results of Cox regression analysis
Variable
HR
95.0% CI for HR
p-value
ED-SCLC Lower Upper
Skin metastases Yes vs No 0.034 0.006 0.192 0.000
LDH < 241 vs. ≥ 241 1.691 1.130 2.530 0.011
Monocytes ≤ 0.84 vs. > 0.84 1.057 0.675 1.655 0.809
NLR < 4 vs. ≥ 4 1.497 0.757 2.961 0.246
NLR < 5 vs. ≥ 5 0.795 0.391 1.615 0.525
LD-SCLC
ECOG 0–1 vs. 2–3 2.865 1.032 7.953 0.043
Chest irradiation Yes vs. No 1.558 0.793 3.047 0.195
PCI Yes vs. No 2.038 0.893 4.654 0.091
Hemoglobin Normal vs. Anemia 1.439 0.773 2.678 0.251
Creatinine Normal vs. Elevated 1.432 0.155 13.198 0.751
CI = confidence interval; ECOG = Eastern Cooperative Oncology Group, ED-SCLC = extensive-
stage disease small cell lung cancer; HR = hazard ratio; LDH = lactate dehydrogenase; LD-SCLC 
= limited-stage disease small cell lung cancer; NLR = neutrophil-to-lymphocyte ratio; PCI = 
prophylactic cranial irradiation
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nostic significance of LMR in SCLC was only in-
vestigated in two studies, both conducted in the 
Asian population.38,41 Out of twelve studies which 
investigated the prognostic value of PLR alone or 
in combination with NLR, only one was done in 
Europe.35 NLR, as the most researched ratio, was 
the subject of investigation in seventeen studies, 
of which only three were European.25,35,42 There are 
only two studies investigating the prognostic role 
of NLR and/or PLR exclusively in the ED group of 
patients.34,43 To our knowledge, to date neither of 
these two parameters have been investigated on a 
European population in cases of extended SCLC. 
As race has been determined as a significant 
prognostic factor in SCLC patients, in the sense 
that being Caucasian represents a favorable inde-
pendent prognostic factor, we were interested in 
whether our results would differ from the ones ob-
tained elsewhere so far.5 
It is important to mention that the results of the 
former studies are inconsistent, that is, some stud-
ies showed a statistically significant correlation 
between the NLR and PLR ratios and overall sur-
vival of the patients, while others did not yield a 
statistical significance. In fact, some studies didn’t 
investigate these ratios in correlation with survival 
at all.44-46 The only prospective study conducted in 
the USA on more than 900 patients verified that 
NLR was a prognostic parameter for OS only in the 
extensive-stage disease group of patients, which is 
consistent with our results.47 The same study estab-
lished that PLR was a prognostic parameter for OS 
only in limited-stage disease, which was different 
from our results. There are no prospective studies 
for LMR. Most retrospective studies which inves-
tigated NLR established its prognostic value, re-
gardless of whether it was investigated in LD, ED, 
or simultaneously in both patient groups. Among 
twelve retrospective studies investigating PLR, 
only three showed a prognostic significance of this 
parameter.48-50 Out of the two studies investigating 
LMR, only one showed a prognostic significance of 
this parameter.38 
In the prospective study mentioned above, 
among other things it was established that NLR 
and PLR were statistically significantly greater in 
patients with extended disease.47 In our study, the 
mean values of NLR and PLR were also higher 
in ED patients, while LMR was higher in LD, al-
though the difference was not statistically signifi-
cant. On the other hand, we found statistically sig-
nificant differences in LMR values in correlation 
with patient age in the ED group, i.e., higher LMR 
values in the younger age group of these patients. 
In spite of the fact that some of our results were 
consistent with those from the only prospective 
study, our study had numerous limitations. In eve-
ry study where data are collected from available re-
cords, there is a possibility that some of it may not 
be reliable, particularly data undergoing subjective 
assessment. As mentioned earlier, performance 
status is one of such parameters, thus making it 
more difficult for analysis in retrospective studies. 
A similar situation may arise in the assessment of 
peripheral lymph node regression during patient 
follow up and evaluation of the response to treat-
ment. 
Furthermore, in the determination of disease ex-
tent, especially in concomitant chemoradiotherapy 
candidates, assessment based only on clinical ex-
amination, bronchoscopy, and CT is not sufficient. 
Since this type of carcinoma is characterized by 
rapid spread, complete staging should be done 
prior to treatment, including brain CT and bone 
scintigraphy. This is the standard procedure at our 
FIGURE 2. Probability of survival of extensive-stage disease small cell lung cancer 
patients according to neutrophil-to-lymphocyte ratio (NLR) cut-off 4 (p = 0.026) and 
NLR cut-off 5 (p = 0.036).
FIGURE 1. Probability of survival of all patients according to stage (p < 0.0001).
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institution today, but was not always possible in 
the past for technical reasons.
The relatively small number of subjects enrolled 
in the study was also a limitation. However, two 
published studies enrolled approximately the 
same number of patients.51,52 Also, some of the 
published studies were conducted in even smaller 
groups of participants.44,51,53 Although some studies 
had a large number of patients, they didn’t analyze 
patients separately considering disease extension.54 
It is important to note that the number of pa-
tients enrolled in the study was probably not ade-
quate for the analysis of certain variables. Namely, 
only a very small number of patients with skin 
metastases and increased creatinine participated 
in the study, as well as very few patients with a 
low performance status. This presents a problem 
for many studies, since low-performance status 
patients are usually not candidates for differential 
treatment and are rarely included in clinical stud-
ies. The same applies for kidney failure patients. 
On the other hand, since the skin is an uncommon 
metastatic site, such patients are rare. Considering 
the confidence interval, it is clear that according to 
this study skin metastases are not a favorable in-
dicator of survival. On the contrary, creatinine can 
be considered a favorable indicator of survival de-
spite the small number of patients.
As far as the investigated treatment procedures 
and their prognostic values are concerned, there 
are certain limitations as well. In the group of all 
patients, statistically significant differences were 
found for survival in relation to PCI and thoracic 
irradiation. However, when the patients were an-
alyzed separately in relation to the extent of the 
disease, those differences disappeared in the ED 
group. This is due to the fact that disease extent 
is one of the most important prognostic factors 
for SCLC, which was established in 2003 in a pro-
spective study involving 436 patients.23 Therefore, 
these two patient groups should always be in-
vestigated separately, because the differences in 
their prognoses entail different modes and aims of 
treatment. In our study, PCI remained prognosti-
cally valuable in the LD patient group, but with an 
insufficient number of subjects for the result to be 
considered reliable. This treatment procedure has 
always been controversial, presenting an issue for 
confrontation and opposing research.55 The prog-
nostic value of PCI was certainly not the primary 
aim of our study. In spite of its limitations, we be-
lieve that our study will contribute to the elucida-
tion of small cell lung cancer, as well as stimulate 
further research on this type of carcinoma, which 
has somehow always remained in the margins of 
lung cancer research.  
Conclusions 
The objective of this study was to determine a 
potential prognostic value of the neutrophil-to-
lymphocyte, platelet-to-lymphocyte, and lym-
phocyte-to-monocyte ratios in patients diagnosed 
with extensive-stage and limited-stage small cell 
lung cancer. To the best of our knowledge, this is 
the first study carried out on a European popula-
tion which analyzed all three of the mentioned ra-
tios. According to the study, NLR could be a good 
prognostic marker in patients with extensive-stage 
SCLC. Further prospective studies are definitely 
needed for this type of cancer.
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